Cargando…

Blood‐based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta‐analysis

AIMS: Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disease. HCM is an important cause of sudden cardiac death and may also lead to outflow tract obstruction and heart failure. Disease severity is highly variable and risk stratification remains limited. Therefore, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Mark, Algül, Sila, Bosman, Laurens P., Michels, Michelle, van der Velden, Jolanda, de Boer, Rudolf A., van Tintelen, J. Peter, Asselbergs, Folkert W., Baas, Annette F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715795/ https://www.ncbi.nlm.nih.gov/pubmed/35842920 http://dx.doi.org/10.1002/ehf2.14073

Ejemplares similares

Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
por: Jansen, Mark, et al.
Publicado: (2023)

Life-long tailoring of management for patients with hypertrophic cardiomyopathy: Awareness and decision-making in changing scenarios
por: Michels, M., et al.
Publicado: (2016)

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status
por: Jansen, M., et al.
Publicado: (2021)

Scientists on the spot: Relaxing the heart in hypertrophic cardiomyopathy
por: Gladka, Monika M, et al.
Publicado: (2023)

Increased Myocardial Oxygen Consumption Precedes Contractile Dysfunction in Hypertrophic Cardiomyopathy Caused by Pathogenic TNNT2 Gene Variants
por: Parbhudayal, Rahana Y., et al.
Publicado: (2020)

Unraveling the Genotype‐Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity‐Related Cardiac Defects as a Major Disease Modifier
por: Nollet, Edgar E., et al.
Publicado: (2020)

Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy
por: Dorsch, Larissa M., et al.
Publicado: (2019)

Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy
por: Nijenkamp, Louise L. A. M., et al.
Publicado: (2020)

Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Myocardial adaptation after surgical therapy differs for aortic valve stenosis and hypertrophic obstructive cardiomyopathy
por: Parbhudayal, Rahana Y., et al.
Publicado: (2019)

In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2014)

Quantitative Approach to Fragmented QRS in Arrhythmogenic Cardiomyopathy: From Disease towards Asymptomatic Carriers of Pathogenic Variants
por: Roudijk, Rob W., et al.
Publicado: (2020)

Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration
por: Nollet, Edgar E, et al.
Publicado: (2023)

Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
por: van Velzen, H. G., et al.
Publicado: (2019)

The effect of inhibition of the Na(+)/H(+) exchanger on the development of hypertrophy in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2011)

Strength of patient cohorts and biobanks for cardiomyopathy research
por: de Boer, R. A., et al.
Publicado: (2020)

Regional myocardial function at preclinical disease stage of hypertrophic cardiomyopathy in female gene variant carriers
por: Parbhudayal, Rahana Y., et al.
Publicado: (2021)

Genotype‐specific pathogenic effects in human dilated cardiomyopathy
por: Bollen, Ilse A. E., et al.
Publicado: (2017)

Diagnosis and Risk Prediction of Dilated Cardiomyopathy in the Era of Big Data and Genomics
por: Sammani, Arjan, et al.
Publicado: (2021)

Translational investigation of electrophysiology in hypertrophic cardiomyopathy
por: Flenner, Frederik, et al.
Publicado: (2021)

Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness
por: Rüssel, Iris K, et al.
Publicado: (2011)

Exercise and myocardial injury in hypertrophic cardiomyopathy
por: Cramer, G Etienne, et al.
Publicado: (2020)

FHL2 expression and variants in hypertrophic cardiomyopathy
por: Friedrich, Felix W., et al.
Publicado: (2014)

Transcriptional bursts and heterogeneity among cardiomyocytes in hypertrophic cardiomyopathy
por: Burkart, Valentin, et al.
Publicado: (2022)

Metabolomics in Severe Aortic Stenosis Reveals Intermediates of Nitric Oxide Synthesis as Most Distinctive Markers
por: van Driel, Beau Olivier, et al.
Publicado: (2021)

The microtubule signature in cardiac disease: etiology, disease stage, and age dependency
por: Algül, Sıla, et al.
Publicado: (2023)

Prevalence and Disease Expression of Pathogenic and Likely Pathogenic Variants Associated With Inherited Cardiomyopathies in the General Population
por: Bourfiss, Mimount, et al.
Publicado: (2022)

A systematic literature review of economic evaluations and cost-of-illness studies of inherited cardiomyopathies
por: Wiethoff, Isabell, et al.
Publicado: (2023)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy
por: McNamara, James W., et al.
Publicado: (2017)

Prognostic significance of anterior mitral valve leaflet length in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
por: van Velzen, Hannah G., et al.
Publicado: (2018)

Contemporary family screening in hypertrophic cardiomyopathy: the role of cardiovascular magnetic resonance( )
por: Huurman, Roy, et al.
Publicado: (2022)

Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect
por: Tadros, Rafik, et al.
Publicado: (2021)

Exercise does not influence development of phenotype in PLN p.(Arg14del) cardiomyopathy
por: van Lint, Freyja H. M., et al.
Publicado: (2023)

Peripartum cardiomyopathy and dilated cardiomyopathy: different at heart
por: Bollen, Ilse A. E., et al.
Publicado: (2015)

Sex differences in the prognosis of patients with hypertrophic cardiomyopathy
por: Kim, Minkwan, et al.
Publicado: (2021)

Oxidative Stress in Dilated Cardiomyopathy Caused by MYBPC3 Mutation
por: Lynch, Thomas L., et al.
Publicado: (2015)

Increasing sensitivity—a common-sense approach?
por: Michels, M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_59rkkou5g76tk12hg4u8c6m2d7